A PYMNTS Company

US: Congress wants Botox buyout review

By  |  June 29, 2014

Seven US Democratic Senators are reportedly calling or regulators to review the proposed acquisition of Allergan, which makes Botox, by Canada’s Valeant Pharmaceuticals.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to reports, lawmakers want the $54 billion hostile takeover offer reviewed, citing former Valeant buyouts that lead to job cuts.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    The company reportedly cut hundreds of jobs in New York after buying Bausch + Lomb.

    Allergan twice has rejected Valeant’s buyout offers, claiming they severely undervalue the US pharmaceutical company. Valeant then joined Allergan shareholder Pershing Square Capital Management for the latest bid in efforts to oust the board of directors to secure the acquisition deal.

    Full content: Democrat and Chronicle

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.